AI & Animal Testing, Future of Drug Safety

AI is transforming drug development and reducing animal testing – the talent needed behind this transformation.

The relationship between drug development and animal testing is undergoing its most significant transformation in decades. Advances in artificial intelligence, combined with landmark regulatory changes, are reshaping how medicines are discovered, tested, and approved – and the life sciences workforce must evolve to match.

A Regulatory Turning Point

In April 2025, the US Food and Drug Administration published an ambitious roadmap to phase out unnecessary animal testing in preclinical safety studies. One year on, the FDA confirmed it has achieved all of its Year 1 goals – qualifying the first AI-based drug development tool for regulatory decision-making, releasing guidance on replacing nonhuman primate testing for monoclonal antibodies, and launching a searchable database of approved alternative methods. As FDA Commissioner Marty Makary stated, the agency is now pursuing “more precise ways of predicting drug safety in humans” – a fundamental shift from decades of animal-first protocols.

The significance of this goes beyond ethics. Historically, more than 90% of drugs that clear animal studies fail to receive FDA approval, largely due to safety or efficacy issues only discovered in human trials. AI-driven New Approach Methodologies (NAMs) – including computational toxicology, organ-on-a-chip systems, and in silico modelling – offer a more human-relevant picture of how drugs behave in the body.

AI Is Already Cutting Timelines and Costs

The commercial case is compelling. According to a September 2025 Reuters investigation, experts across biotech, contract research organisations, and financial analysis firms believe that combining AI with reduced animal testing could cut drug development timelines and costs by at least 50% within three to five years. One example: Recursion Pharmaceuticals moved a cancer drug candidate from molecule to clinical testing in just 18 months using its AI platform – compared to an industry average of 42 months. Analysts at TD Cowen and Jefferies project that AI-driven approaches could compress development from up to 15 years and $2 billion to a fraction of that.

These are not distant promises. The NIH announced in July 2025 that it would no longer fund research projects focused solely on animal testing, and the FDA Modernization Act 3.0, passed by the US Senate in December 2025, went further than its predecessor by creating a formal qualification process for NAMs. The direction of travel is unambiguous.

The Human Talent Behind the AI Revolution

AI cannot execute this transition alone – but the talent challenge is more specific than it first appears. There is no shortage of AI engineers, and no shortage of life scientists. What is genuinely scarce are people who sit credibly between the two: professionals who understand both domains well enough to work at the boundary where the real problems live.

Companies consistently struggle to find biologists who understand how machine learning models are actually built – and crucially, where they can fail. A biologist who cannot interrogate a model’s training data, spot overfitting, or challenge an anomalous output is not equipped to work safely in this space. Equally, ML engineers who have only ever worked with clean, well-structured datasets are often unprepared for the complexity of real biological and clinical data – messy, incomplete, context-dependent, and full of edge cases that can quietly undermine a model’s reliability.

There is also a growing and underserved need for scientists who can sense-check AI outputs and translate them into language that regulators are comfortable with. This is not a communications role – it requires genuine scientific depth combined with an understanding of how regulatory bodies evaluate evidence, what they will and will not accept, and how to construct a submission that holds up to scrutiny. As NAMs become central to drug approval processes, this capability will move from niche to essential.

The Most In-Demand Talent

The most in-demand profiles reflect these overlapping demands. Biology combined with machine learning is perhaps the most critical pairing – people who can design experiments with modelling in mind, and challenge model outputs with domain expertise. Toxicology or pharmacology combined with data science is seeing particularly strong demand, as organisations need specialists who can interpret computational safety predictions and stand behind them professionally. Regulatory science combined with AI literacy is a third connector role that teams are consistently missing – the person who can bridge what the model says and what the agency needs to hear.

These are not hybrid roles in the sense of doing two jobs at once. They are a distinct professional profile: people who have built genuine fluency across disciplines and can operate as connectors within multidisciplinary teams. They are also, almost by definition, not actively looking – they tend to be highly valued wherever they are.

Why Partner With a Specialist Life Science Recruiter

The talent required to drive this transition sits at an intersection that very few candidates – and very few generalist recruiters – understand. A computational biologist who also grasps FDA regulatory submissions, or a toxicologist fluent in machine learning validation frameworks, is not found through a standard job board search.

A specialist life science recruiter brings pre-built networks within these niche communities, an understanding of the specific competency profiles that matter, and the ability to assess scientific credibility alongside cultural and organisational fit. They can move quickly in a competitive talent market where biotech, pharma, and AI technology companies are all competing for the same rare profiles.

Beyond individual hires, a specialist recruitment partner can advise on workforce planning – helping organisations map the roles they will need as AI tooling matures, as regulatory requirements shift, and as the pipeline of NAM-qualified drugs begins to grow. In a field defined by rapid change, that strategic perspective is as valuable as any single placement.

The science of drug development is being rewritten. The organisations that get ahead will be those that invest in the right human expertise now – before the skills gap becomes a competitive disadvantage.

By Nathan Sharpe, Team Lead, Skills Alliance